![]() h, i, Weight change (P = 9.2E-4) and cumulative food intake (P = 8.9E-6 by two-way ANOVA with Sidak correction for h and i) of wild-type and HDAC6 KO DIO mice treated daily with i.p. f, g, Body weight change of DIO wild-type mice treated daily with vehicle (n = 12), ricolinostat (25 mg/kg, i.p., n = 12, P = 2.7E-7 by two-way ANOVA with Sidak correction) (f) or CAY10603 (12.5 mg/kg, i.p., n = 4, P = 2.5E-9 by two-way ANOVA with Sidak correction) (g). TubA P = 1.4E-6, two-way ANOVA with Tukey post-hoc test) of vehicle, tubastatin, or BRD3067-treated DIO wild-type mice (n = 6). TubA P = 2.0E-3) and food intake (day 1 BRD3067 vs. Immunoblots from 293 T lysates 24 hr after drug treatment. c, Structure of tubastatin and BRD3067 (top). ![]() ![]() b, Body weight of daily vehicle (n = 5) or tubastatin (i.p., 12.5 mg/kg, n-6) treated DIO HDAC6 KO mice. HDAC6-specific Weight Loss response to HDAC6 inhibitorsĪ, Growth curves of WT (n = 18 mice) and HDAC6 KO (n = 12 mice) mice on high fat diet (left) and their body composition (right).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |